Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 112

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 112
---
 ​ | ​ | ​                 | ​ | ​ | ​                     | ​ | ​ | ​                         | ​ | ​ |                                             | ​ | ​ | ​                     | ​ | ​ | ​          | ​ | ​ | ​          | ​ |
| ​ | 2025PROXY STATEMENT SUMMARY | ​ | ​ | CORPORATEGOVERNANCEAND BOARDMATTERS | ​ | ​ | AUDITMATTERS | ​ | ​ | EXECUTIVEOFFICERS | ​ | ​ | EXECUTIVECOMPENSATION | ​ | ​ | STOCKOWNERSHIPINFORMATION | ​ | ​ | INFORMATIONABOUT THEANNUALMEETING ANDVOTING | ​ | ​ | ADDITIONALINFORMATION | ​ | ​ | APPENDIX A | ​ | ​ | APPENDIX B | ​ |

TABLE OF CONTENTS Information about the Annual Meeting and Voting

| ​ | ​ | Information about the Annual Meeting and Voting | ​ |

All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board with respect to each of the matters set forth in the accompanying notice of the Annual Meeting. Purpose of the Annual Meeting and Board Voting Recommendations At the Annual Meeting, our stockholders will consider and vote on the following matters:

| Proposal 
 1        
 2        | ​ 
 ​ | ​ 
 ​ | Election of three Class II directors to our board of directors to serve until the 2028 annual meeting of stockholders                         
 Ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | BoardRecommendations 
 FOReachnominee       
 FOR                  | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | For MoreInformation, See Page 
                            16 
                            42 | ​ 
 ​ 
 ​ |
|:---------|:--|:--|:----------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|:---------------------|:--|:--|------------------------------:|:--|
| 3        | ​ | ​ | Approval, on an advisory basis, of the compensation of our named executive officers                                                           | ​ | ​ | FOR                  | ​ | ​ |                            50 | ​ |
| 4        | ​ | ​ | Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named executive officers                   |